Last updated on March 2020

Human Mesenchymal Stem Cells (LMSCs) on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty

Brief description of study

This is a phase I/II, randomized, blinded and placebo-controlled study to test the safety and efficacy of LMCSs for improving vaccine immune response.

Detailed Study Description

A pilot phase will consist of a 3 subject safety run-in, followed by 20 subject randomized phase to evaluate influenza vaccine response at 1 week and 4 weeks post infusion of LMSCs. This will be followed by a double-blinded, randomized, placebo-controlled phase.

Clinical Study Identifier: NCT02982915

Find a site near you

Start Over

Vista Health Research

Miami, FL United States
  Connect »

Clinical Physiology Associates

Fort Myers, FL United States
  Connect »

Clinical Research of South Florida

Coral Gables, FL United States
  Connect »

University of Miami

Miami, FL United States
  Connect »

Johns Hopkins University

Baltimore, MD United States
  Connect »

Optimal Research LLC

Rockville, MD United States
  Connect »